Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies

被引：5
|
作者：
El Ali, Ziad [1 ]
Rottey, Sylvie [2 ]
Barthelemy, Philippe [3 ]
Kotecki, Nuria [1 ,4 ]
Van Paemel, Ruben [2 ]
Devrient, Daniel [5 ]
Awada, Ahmad [1 ]
Gil, Thierry [1 ]
Pannier, Diane [4 ]
Ryckewaert, Thomas [4 ]
Waisse, Waissi [6 ]
Clavier, Jean-Baptiste [6 ]
Penel, Nicolas [4 ]
Vermassen, Tijl [2 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, 121-125 Blvd Waterloo, Brussels, Belgium
[2] Ghent Univ Hosp, Dept Med Oncol, Ghent, Belgium
[3] Hopi Univ Strasbourg, Dept Med Oncol, Strasbourg, France
[4] Ctr Oscar Lambret, Dept Gen Oncol, Lille, France
[5] Inst Jules Bordet, Dept Radiotherapy, Brussels, Belgium
[6] Comprehens Canc Ctr Paul Strauss, Dept Radiat Oncol, Strasbourg, France
来源：
ANTICANCER RESEARCH | 2019年 / 39卷 / 06期
关键词：
Brain metastasis; renal cell carcinoma; survival; prognostic factors; PHASE-III; RADIATION-THERAPY; STEREOTACTIC RADIOSURGERY; SURVIVAL; EVEROLIMUS; SORAFENIB; PAZOPANIB; SYSTEMS; MODEL; TRIAL;
D O I：
10.21873/anticanres.13431
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: This study aimed at exploring several brain metastatic prognostic scores in patients with renal cell carcinoma. Patients and Methods: We retrospectively analyzed data of 93 metastatic renal cell carcinoma patients who were diagnosed with brain metastases between October 2005 and July 2016 who received targeted therapy. Potential prognostic factors (RTOG RPA, BS-BM, and a newly developed score CERENAL) were analyzed. Results: A total of 75 patients received targeted therapy. All scores showed prognostic value in progression-free survival after first-line treatment with CERENAL being the sole independent prognostic factor associated with improved duration of first-line treatment. Both RTOG RPA and CERENAL were potential prognosticators for overall survival, whereas only the CERENAL score was associated with prolonged disease-specific survival. Conclusion: Several prognostic scores can be useful to predict survival of patients with brain metastases from renal cancer, especially the newly developed CERENAL score.
引用
收藏
页码：2993 / 3002
页数：10
相关论文
共 50 条
  • [31] Update on targeted therapies for clear cell renal cell carcinoma
    Singer, Eric A.
    Gupta, Gopal N.
    Srinivasan, Ramaprasad
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (03) : 283 - 289
  • [32] Outcomes of palliative surgery for bone metastasis of metastatic renal cell carcinoma in the era of targeted therapy
    Hara, Hitomi
    Kawamoto, Teruya
    Fukase, Naomasa
    Sawada, Ryoko
    Fujiwara, Shuichi
    Yahiro, Shunsuke
    Miyamoto, Tomohiro
    Terakawa, Tomoaki
    Mifune, Yutaka
    Hoshino, Yuichi
    Kakutani, Kenichiro
    Matsumoto, Tomoyuki
    Matsushita, Takehiko
    Niikura, Takahiro
    Kuroda, Ryosuke
    Akisue, Toshihiro
    EJSO, 2023, 49 (05): : 928 - 933
  • [33] Sunitinib and other targeted therapies for renal cell carcinoma
    Powles, T.
    Chowdhury, S.
    Jones, R.
    Mantle, M.
    Nathan, P.
    Bex, A.
    Lim, L.
    Hutson, T.
    BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 741 - 745
  • [34] Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma
    Pracht, Marc
    Berthold, Dominik
    SUCCESSES AND LIMITATIONS OF TARGETED CANCER THERAPY, 2014, 41 : 98 - 112
  • [35] Selecting Targeted Therapies for Patients With Renal Cell Carcinoma
    Plimack, Elizabeth R.
    Hudes, Gary R.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (09): : 997 - 1007
  • [36] Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
    Seront, Emmanuel
    Machiels, Jean-Pascal
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 146 - 156
  • [37] New Treatments for Renal Cell Carcinoma: Targeted Therapies
    Saylor, Philip J.
    Michaelson, M. Dror
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (06): : 645 - 656
  • [38] Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
    Matrana, Marc R.
    Atkinson, Bradley
    Jonasch, Eric
    Tannir, Nizar M.
    CURRENT CLINICAL PHARMACOLOGY, 2011, 6 (03): : 189 - 198
  • [39] Sunitinib and other targeted therapies for renal cell carcinoma
    T Powles
    S Chowdhury
    R Jones
    M Mantle
    P Nathan
    A Bex
    L Lim
    T Hutson
    British Journal of Cancer, 2011, 104 : 741 - 745
  • [40] Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies
    Rebibo, J. D.
    Pfister, C.
    Giwerc, A.
    Defortescu, G.
    Gouerant, S.
    Di Fiore, F.
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2016, 26 (01): : 16 - 23
12345